J&J's Imaavy approved for warm autoimmune hemolytic anemia; Takeda's Orzeyful & Rhythm's Imcivree approved in Japan; Basking's BB-025 reverses stroke drug BB-031.
J&J’s Imaavy wins label expansion: The monoclonal antibody is now the first treatment approved specifically for warm autoimmune hemolytic anemia, a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Johnson & Johnson scores 1st FDA label expansion for Imaavy
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment - Johnson & Johnson (NYSE:JNJ)
First Drug OK'd for Warm Autoimmune Hemolytic Anemia
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera
Just 16 months after Johnson & Johnson scored its initial FDA app | Sixteen months after Johnson & Johnson scored its initial FDA…
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults…
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck…
Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority…
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
Trial data showed significant increases in durable hemoglobin responses versus placebo
